M E Pavel

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. ncbi request reprint Impact of growth hormone on central nervous activity, vigilance, and tiredness after short-term therapy in growth hormone-deficient adults
    M E Pavel
    Division of Endocrinology, Department of Internal Medicine I, University of Erlangen Nurnberg, Germany
    Horm Metab Res 35:114-9. 2003
  2. ncbi request reprint Long-term follow-up of childhood-onset hypopituitarism in patients with the PROP-1 gene mutation
    Marianne E Pavel
    Division of Endocrinology, Department of Internal Medicine I, University Erlangen Nurnberg, Germany
    Horm Res 60:168-73. 2003
  3. ncbi request reprint Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors
    Marianne E Pavel
    Department of Medicine I, University of Erlangen Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany
    Int J Gastrointest Cancer 35:179-85. 2005
  4. ncbi request reprint Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas
    Marianne E Pavel
    Department of Medicine I, University Hospital Erlangen Nuremberg, 91054 Erlangen, Germany
    J Interferon Cytokine Res 26:8-13. 2006
  5. ncbi request reprint Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas
    M E Pavel
    Division of Endocrinology, Department of Medicine I, Erlangen Nürnberg University Hospital, Germany
    Horm Metab Res 38:112-8. 2006
  6. ncbi request reprint Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas
    Marianne E Pavel
    Department of Medicine I, University Hospital Erlangen Nuernberg, Ulmensweg 18, 91054 Erlangen, Germany
    Clin Endocrinol (Oxf) 62:434-43. 2005
  7. ncbi request reprint Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)
    Ola Nilsson
    Department of Pathology, Gothenburg University, Gothenburg, Sweden
    Neuroendocrinology 84:212-5. 2006
  8. ncbi request reprint Poorly-differentiated endocrine carcinomas of midgut and hindgut origin
    Hakan Ahlman
    Department of Surgery, Sahlgrenska University Hospital, Goteborg, Sweden
    Neuroendocrinology 87:40-6. 2008

Detail Information

Publications8

  1. ncbi request reprint Impact of growth hormone on central nervous activity, vigilance, and tiredness after short-term therapy in growth hormone-deficient adults
    M E Pavel
    Division of Endocrinology, Department of Internal Medicine I, University of Erlangen Nurnberg, Germany
    Horm Metab Res 35:114-9. 2003
    ..Although results must be interpreted cautiously due to the small sample size, we conclude that the improved sleep and mood parameters might be caused by other indices of general well-being in our study...
  2. ncbi request reprint Long-term follow-up of childhood-onset hypopituitarism in patients with the PROP-1 gene mutation
    Marianne E Pavel
    Division of Endocrinology, Department of Internal Medicine I, University Erlangen Nurnberg, Germany
    Horm Res 60:168-73. 2003
    ..The PROP-1 gene mutation is a rare disorder leading to combined pituitary hormone deficiencies over time. The aim was to analyze the clinical picture of 40 years of an almost untreated PROP-1 gene mutation...
  3. ncbi request reprint Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors
    Marianne E Pavel
    Department of Medicine I, University of Erlangen Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany
    Int J Gastrointest Cancer 35:179-85. 2005
    ..It is not clear what therapy should be applied after failed biotherapy. Our aim was to establish whether patients whose tumors rapidly progress under biotherapy may benefit from chemotherapy...
  4. ncbi request reprint Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas
    Marianne E Pavel
    Department of Medicine I, University Hospital Erlangen Nuremberg, 91054 Erlangen, Germany
    J Interferon Cytokine Res 26:8-13. 2006
    ..Better tolerability of PEG-IFN-alpha2b improved patients' compliance, justifying its use in patients who do not tolerate conventional IFN-alpha treatment...
  5. ncbi request reprint Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas
    M E Pavel
    Division of Endocrinology, Department of Medicine I, Erlangen Nürnberg University Hospital, Germany
    Horm Metab Res 38:112-8. 2006
    ..Adrenomedullin might represent a useful prognostic marker in patients with neuroendocrine carcinomas...
  6. ncbi request reprint Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas
    Marianne E Pavel
    Department of Medicine I, University Hospital Erlangen Nuernberg, Ulmensweg 18, 91054 Erlangen, Germany
    Clin Endocrinol (Oxf) 62:434-43. 2005
    ..The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation...
  7. ncbi request reprint Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic)
    Ola Nilsson
    Department of Pathology, Gothenburg University, Gothenburg, Sweden
    Neuroendocrinology 84:212-5. 2006
  8. ncbi request reprint Poorly-differentiated endocrine carcinomas of midgut and hindgut origin
    Hakan Ahlman
    Department of Surgery, Sahlgrenska University Hospital, Goteborg, Sweden
    Neuroendocrinology 87:40-6. 2008